Abbott enrolls first patient in SCS/CMM trial to treat chronic low back pain
Abbott declared the first patient has been enrolled in the DISTINCT study (Dorsal spInal cord STImulatioN vs mediCal management for
Read more
Neurology
New data reveals Roche’s OCREVUS is highly effective for RRMS
Swiss pharma giant Roche announced today new data that demonstrates OCREVUS® (ocrelizumab) is a highly effective treatment option for people
Read more
Sunovion gets FDA nod for KYNMOBI™ as Parkinson’s Disease treatment
Sunovion has announced it has received approval from the FDA for KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the treatment of
Read more
Pfizer’s gene therapy promising for Duchenne muscular dystrophy (DMD)
Pfizer Inc. has revealed revised clinical Phase 1b results on PF-06939926, an investigational gene therapy to treat Duchenne muscular dystrophy
Read more
Roche’s OCREVUS (ocrelizumab) can half risk of MS impairment advance
New post-hoc analysis of six years of study data for Roche’s OCREVUS (ocrelizumab) shows earlier treatment initiation nearly halves the
Read more
SPRAVATO™ Nasal Spray (esketamine) Licensed in EU for treatment-resistant MDD
Esketamine is used as a fast-acting nasal spray treating patients who have not reacted well to conventional antidepressants. It is used
Read more